Karyopharm Therapeutics (KPTI) Enterprise Value (2016 - 2025)
Karyopharm Therapeutics (KPTI) has disclosed Enterprise Value for 14 consecutive years, with -$50.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 53.14% year-over-year to -$50.9 million, compared with a TTM value of -$50.9 million through Dec 2025, up 53.14%, and an annual FY2025 reading of -$50.9 million, up 53.14% over the prior year.
- Enterprise Value was -$50.9 million for Q4 2025 at Karyopharm Therapeutics, down from -$45.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$45.9 million in Q3 2025 and bottomed at -$260.4 million in Q1 2023.
- Average Enterprise Value over 5 years is -$139.4 million, with a median of -$146.1 million recorded in 2022.
- The sharpest move saw Enterprise Value soared 76.35% in 2022, then plummeted 390.65% in 2023.
- Year by year, Enterprise Value stood at -$228.6 million in 2021, then soared by 37.08% to -$143.8 million in 2022, then tumbled by 33.09% to -$191.4 million in 2023, then surged by 43.21% to -$108.7 million in 2024, then soared by 53.14% to -$50.9 million in 2025.
- Business Quant data shows Enterprise Value for KPTI at -$50.9 million in Q4 2025, -$45.9 million in Q3 2025, and -$47.9 million in Q2 2025.